论文部分内容阅读
将病毒性呼吸道感染 2 4 0例随机分为丽科韦治疗组 1 2 0例及干扰素对照组1 2 0例 ,对其疗效及副作用进行比较 ,结果 :治疗组 1 2 0例中 ,痊愈 60例 ,显效 2 4例 ,有效 36例 ,无效 0例 ,疗效评价 83% ,总有效率 1 0 0 %。对照组 1 2 0例中 ,痊愈 60例 ,显效 2 0例 ,有效 40例 ,无效 0例 ,疗效评价 85 % ,总有效率 1 0 0 %。治疗组和对照组无明显差异 ( P>0 .0 5 )。提示应用丽科韦治疗病毒性呼吸道感染是目前安全有效广谱的抗病毒药
A total of 240 cases of viral respiratory infections were randomly divided into 120 cases of rifoveicin treatment group and 120 cases of interferon control group, the efficacy and side effects were compared, the results: 120 cases of treatment group, healed 60 cases, effective in 24 cases, effective in 36 cases, 0 cases, 83% of the efficacy evaluation, the total efficiency of 100%. In the control group, 120 cases were cured, 20 cases were markedly effective, 40 cases were effective and 0 was ineffective. The curative effect was 85% and the total effective rate was 100%. There was no significant difference between the treatment group and the control group (P> 0.05). Prompt application of lycovir for the treatment of viral respiratory infections is currently a safe and effective broad-spectrum anti-viral drug